Small Molecules to Treat Cardiovascular Disease: Cardiac Myosin Inhibitors

References

[1] Cheng Y, Dong S, Shen P, Sun Y, Lin H, Zhai S. Achievement of low-density lipoprotein cholesterol targets in Chinese patients with atherosclerotic cardiovascular disease after receiving statins and ezetimibe. Front Cardiovasc Med. 2022. Vol. 9:988576

[2] Shahim B, Kapelios CJ, Savarese G, Lund LH. Global public health burden of heart failure: an updated review. Card Fail Rev. 2023. Vol. 9:e11

[3] Writing Committee Members. Ommen SR, Ho CY, Asif IM, Balaji S, Burke MA, et al.. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2024. Vol. 83(23):2324-405

[4] Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al.. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019. Vol. 74(10):1376-414

[5] Writing Committee. Kittleson MM, Ruberg FL, Ambardekar AV, Brannagan TH, Cheng RK, et al.. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023. Vol. 81(11):1076-126

[6] Arca M, D’Erasmo L, Cuchel M, Blom DJ, Cegla J, Duell PB, et al.. Long-term experience with lomitapide treatment in patients with homozygous familial hypercholesterolemia: over 10 years of efficacy and safety data. J Clin Lipidol. 2025. Vol. 19(4):775-89

[7] Patel AGM, Li P, Badrish N, Kesari A, Shah KB. Transthyretin cardiac amyloidosis: current and emerging therapies. Curr Cardiol Rep. 2025. Vol. 27(1):33

[8] Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, et al.. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med. 2021. Vol. 384(2):105-16

[9] Kawana M, Spudich JA, Ruppel KM. Hypertrophic cardiomyopathy: mutations to mechanisms to therapies. Front Physiol. 2022. Vol. 13:975076

[10] Aronson D, Krum H. Novel therapies in acute and chronic heart failure. Pharmacol Ther. 2012. Vol. 135(1):1-17

[11] Green EM, Wakimoto H, Anderson RL, Evanchik MJ, Gorham JM, Harrison BC, et al.. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science. 2016. Vol. 351(6273):617-21

[12] Chuang C, Collibee S, Ashcraft L, Wang W, Vander Wal M, Wang X, et al.. Discovery of aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy. J Med Chem. 2021. Vol. 64(19):14142-52

[13] Auguin D, Robert-Paganin J, Réty S, Kikuti C, David A, Theumer G, et al.. Omecamtiv mecarbil and Mavacamten target the same myosin pocket despite opposite effects in heart contraction. Nat Commun. 2024. Vol. 15(1):4885

[14] Hartman JJ, Hwee DT, Robert-Paganin J, Chuang C, Chin ER, Edell S, et al.. Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy. Nat Cardiovasc Res. 2024. Vol. 3(8):1003-16

[15] Grillo MP, Erve JCL, Dick R, Driscoll JP, Haste N, Markova S, et al.. In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin. Xenobiotica. 2019. Vol. 49(6):718-33

[16] Coats CJ, Masri A, Nassif ME, Barriales-Villa R, Arad M, Cardim N, et al.. Dosing and safety profile of aficamten in symptomatic obstructive hypertrophic cardiomyopathy: results from SEQUOIA-HCM. J Am Heart Assoc. 2024. Vol. 13(15):e035993

[17] Olivotto I, Oreziak A, Barriales-Villa R, Abraham TP, Masri A, Garcia-Pavia P, et al.. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020. Vol. 396(10253):759-69

[18] Desai MY, Owens A, Geske JB, Wolski K, Naidu SS, Smedira NG, et al.. Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy. J Am Coll Cardiol. 2022. Vol. 80(2):95-108

[19] Tian Z, Li L, Li X, Wang J, Zhang Q, Li Z, et al.. Effect of mavacamten on Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: the EXPLORER-CN randomized clinical trial. JAMA Cardiol. 2023. Vol. 8(10):957-65

[20] Maron MS, Masri A, Nassif ME, Barriales-Villa R, Arad M, Cardim N, et al.. Aficamten for symptomatic obstructive hypertrophic cardiomyopathy. N Engl J Med. 2024. Vol. 390(20):1849-61

[21] Garcia-Pavia P, Maron MS, Masri A, Merkely B, Nassif ME, Peña-Peña ML, et al.. Aficamten or metoprolol monotherapy for obstructive hypertrophic cardiomyopathy. N Engl J Med. 2025. Vol. 393(10):949-60

[22] Davis BJ, Volk H, Nguyen O, Kamna D, Chen H, Barriales-Villa R, et al.. Safety and efficacy of mavacamten and aficamten in patients with hypertrophic cardiomyopathy. J Am Heart Assoc. 2025. Vol. 14(6):e038758

[23] Saberi S, Abraham TP, Choudhury L, Barriales-Villa R, Elliott PM, Nassif ME, et al.. Aficamten treatment for symptomatic obstructive hypertrophic cardiomyopathy: 48-week results from FOREST-HCM. JACC Heart Fail. 2025. Vol. 13(8):102496

[24] Ho CY, Mealiffe ME, Bach RG, Bhattacharya M, Choudhury L, Edelberg JM, et al.. Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2020. Vol. 75(21):2649-60

[25] Desai MY, Owens AT, Abraham T, Olivotto I, Garcia-Pavia P, Lopes RD, et al.. Mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy. N Engl J Med. 2025. Vol. 393(10):961-72